Rocio Garcia-Carbonero, MD, of Hospital Universitario 12 De Octubre, discusses results of the phase II/III AXINET trial, which showed that axitinib plus long-acting release octreotide improved overall response compared with placebo and octreotide in patients with advanced grade 1 or 2 extrapancreatic neuroendocrine tumors. However, no significant improvement in progression-free survival was observed (Abstract 360).
Kai-Keen Shiu, MD, PhD, of the University College Hospital NHS Foundation Trust - London, discusses an interim analysis of PFS 2 results (defined as...
Richard S. Finn, MD, of the UCLA Medical Center, discusses updated results from the IMbrave 150 study, which showed atezolizumab plus bevacizumab provides the longest overall...
Wasat Mansoor, MBChB, PhD, of The Christie NHS Foundation Trust, discusses phase III results from the KEYNOTE-590 trial, which showed no deterioration in health-related quali...
Tenna V. Henriksen, PhD Candidate, of Aarhus University, discusses her findings on how circulating tumor DNA may help assess recurrence risk and the benefit of adjuvant thera...
Zev A. Wainberg, MD, of UCLA Medical Center, discusses phase II results from the FIGHT study, which combined bemarituzumab with modified FOLFOX6 in first-line treatment of ad...